YoungEWhangMD

Oncology • Chapel Hill, NC

Genitourinary Oncology

Associate Professor, Medicine, University of North Carolina at Chapel Hill School of Medicine

Join to view full profile

Dr. Whang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Whang's full profile

Already have an account?

Office
101 Manning Dr
Chapel Hill, NC 27514
Phone+1 984-974-0000

Fax+1 919-966-7772

Education & Training

Ronald Reagan UCLA Medical CenterPost-Doctoral Fellowship, 1996 - 1998
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1993 - 1996
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1990 - 1993
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1990, MD

Certifications & Licensure

NC State Medical License 1998 - 2025
CA State Medical License 1991 - 1998
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer Start of enrollment: 2009 May 01
Completed
Phase 1
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2012 Mar 30
Completed
Phase 2
Cardiovascular Risk and Preventive Care in Prostate Cancer Patients Receiving Radiation and Hormone Therapy Start of enrollment: 2012 Jun 01
Completed
Using Walk With Ease Walking Program With Men 65 and Older Being Treated for Prostate Cancer Start of enrollment: 2013 Oct 01
Terminated
Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer Start of enrollment: 2015 Jul 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
Real-World Incidence and Severity of Hypertension Caused by Abiraterone Acetate in Patients With Metastatic Prostate Cancer.
Brian Lam, Jo E Rodgers, Benyam Muluneh, Darrian Proco, Young E Whang
The Annals of Pharmacotherapy. 2024-10-01
2 citations
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).
Maha Hussain, Masha Kocherginsky, Neeraj Agarwal, Nabil Adra, Jingsong Zhang
Clinical Cancer Research. 2024-10-01
Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States.
Emily M Rencsok, Natalie Slopen, Hannah D McManus, Karen A Autio, Alicia K Morgans
Cancer Research Communications. 2024-01-08

Journal Articles

Article ZFX Mediates Non-Canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer
Young Whang, MD, ScienceDirect

Grant Support

Regulation Of Androgen Receptor By HER-2 And Ack1 Tyrosine KinasesNational Cancer Institute2008–2012
Functional Analysis Of PTEN In Prostate CancerNational Cancer Institute2000–2005
Targeted Therapy Of Prostate CancerNational Cancer Institute2003–2004

Professional Memberships

American Society of Clinical Oncology - ASCO
Member